|
Coronary Arteriosclerosis
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
The functional variant rs9267551 C, in the promoter region of DDAH2, has been linked to increased DDAH2 expression, and lower ADMA plasma levels, and was associated with lower risk of coronary artery disease in large-scale genome-wide association studies (GWAS) performed in the general population.
|
31409409 |
2019 |
|
Coronary Artery Disease
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
The functional variant rs9267551 C, in the promoter region of DDAH2, has been linked to increased DDAH2 expression, and lower ADMA plasma levels, and was associated with lower risk of coronary artery disease in large-scale genome-wide association studies (GWAS) performed in the general population.
|
31409409 |
2019 |
|
Coronary Arteriosclerosis
|
0.330 |
PosttranslationalModification
|
disease |
BEFREE |
Hypermethylation of DDAH2 promoter contributes to the dysfunction of endothelial progenitor cells in coronary artery disease patients.
|
24934151 |
2014 |
|
Coronary Artery Disease
|
0.330 |
PosttranslationalModification
|
disease |
BEFREE |
DDAH2 promoter in EPCs from CAD patients was hypermethylated and the methylation level was negatively correlated to DDAH2 mRNA level and adhesion function of EPCs.
|
24934151 |
2014 |
|
Coronary Arteriosclerosis
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
Association study of dimethylarginine dimethylaminohydrolase 2 gene polymorphisms and coronary heart disease.
|
22923027 |
2012 |
|
Coronary Artery Disease
|
0.330 |
GeneticVariation
|
disease |
BEFREE |
Association study of dimethylarginine dimethylaminohydrolase 2 gene polymorphisms and coronary heart disease.
|
22923027 |
2012 |
|
Coronary Arteriosclerosis
|
0.330 |
Biomarker
|
disease |
CTD_human |
Role of nitric oxide-producing and -degrading pathways in coronary endothelial dysfunction in chronic kidney disease.
|
17267746 |
2007 |
|
Coronary Artery Disease
|
0.330 |
Biomarker
|
disease |
CTD_human |
Role of nitric oxide-producing and -degrading pathways in coronary endothelial dysfunction in chronic kidney disease.
|
17267746 |
2007 |
|
Pre-Eclampsia
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
In pre-eclampsia, we found only weak correlations between maternal ADMA levels and DDAH 1 (r=-0.41; p=0.22) and DDAH 2 expressions (r=-0.45; p=0.17) but a slightly stronger correlation between DDAH 2 expression and feto-maternal ADMA gradient (r=0.60; p=0.07).
|
22285683 |
2012 |
|
Endothelial dysfunction
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Our previous study demonstrated that VPO1 plays a critical role in endothelial dysfunction through dimethylarginine dimethylaminohydrolase2 (DDAH2)/asymmetric Dimethylarginine (ADMA) pathway.
|
28264790 |
2017 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
To investigate determinants of asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA), including single nucleotide polymorphisms (SNPs), in the DDAH1, DDAH2, and AGXT2 genes and their associations with prevalent and incident cardiovascular disease (CVD) in older adults with type 2 diabetes mellitus.
|
24186881 |
2014 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
In the present study, we found that SNP rs2272592 in DDAH2 is associated with type 2 diabetes but SNP rs805304 in DDAH2 is not.
|
22579530 |
2012 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Examining data from the DIAGRAM+ (Diabetes Genetics Replication And Meta-analysis), we identified a variant (rs9267551) in the DDAH2 gene nominally associated with type 2 diabetes (P = 3 × 10(-5)).
|
22558392 |
2012 |
|
Endothelial dysfunction
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
These results indicate that suppression of DDAH2 expression is a culprit for homocysteine-induced impairments of DDAH/ADMA/NOS/NO pathway in endothelial cells, and therapeutic manipulation of DDAH2 expression may be a promising strategy for preventing endothelial dysfunction and cardiovascular diseases associated with hyperhomocysteinemia.
|
23171931 |
2012 |
|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
We sought to determine whether serum ADMA levels in type 2 diabetes are influenced by common polymorphisms in the DDAH1 and DDAH2 genes.
|
20209122 |
2010 |
|
Endothelial dysfunction
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
DDAH2 overexpression not only improved endothelial dysfunction in diabetic aortas but also attenuated hyperglycemia-induced changes in DDAH/ADMA//NO pathway in endothelial cells.
|
19775692 |
2010 |
|
Endothelial dysfunction
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
In this review, the recent advances in the regulation and function of DDAH enzymes, their roles in the regulation of NO generation, and their possible contribution to endothelial dysfunction in patients with cardiovascular and kidney diseases are discussed.
|
17933965 |
2007 |
|
Coronary heart disease
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
The functional variant rs9267551 C, in the promoter region of DDAH2, has been linked to increased DDAH2 expression, and lower ADMA plasma levels, and was associated with lower risk of coronary artery disease in large-scale genome-wide association studies (GWAS) performed in the general population.
|
31409409 |
2019 |
|
Diabetes Mellitus
|
0.030 |
Biomarker
|
group |
BEFREE |
Considering the involvement of dimethylarginine dimethylaminohydrolase 2 (DDAH2) in diabetes, it was hypothesized that DDAH2 may be beneficial to cardiac function and myocardial fibrosis during the progression of DCM with involvement of the DDAH/asymmetric NG, NGdimethyl‑L‑arginine (ADMA)/nitric oxide synthase (NOS)/nitric oxide (NO) signaling pathway.
|
30569164 |
2019 |
|
Diabetes Mellitus
|
0.030 |
Biomarker
|
group |
BEFREE |
Our data demonstrated that inducible nitric oxide synthase/gamma-Glutamyl-cysteine ligase (iNOS/GGCL) and DDAH dysregulation may play a key role in high glucose mediated oxidative stress, whereas HO-1 inducers such as CAPE or its more potent derivatives may be useful in diabetes and other stress-induced pathological conditions.
|
31108850 |
2019 |
|
Hypertensive disease
|
0.030 |
Biomarker
|
group |
BEFREE |
We conducted a case-control study on a Chinese population that included three ethnic groups (Han, Kazakh and Uygur), to systemically investigate associations between variations in the genes DDAH1 and DDAH2 and hypertension.
|
26786611 |
2016 |
|
Cardiovascular Diseases
|
0.030 |
GeneticVariation
|
group |
BEFREE |
To investigate determinants of asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA), including single nucleotide polymorphisms (SNPs), in the DDAH1, DDAH2, and AGXT2 genes and their associations with prevalent and incident cardiovascular disease (CVD) in older adults with type 2 diabetes mellitus.
|
24186881 |
2014 |
|
Coronary heart disease
|
0.030 |
PosttranslationalModification
|
disease |
BEFREE |
Hypermethylation of DDAH2 promoter contributes to the dysfunction of endothelial progenitor cells in coronary artery disease patients.
|
24934151 |
2014 |
|
Cardiovascular Diseases
|
0.030 |
AlteredExpression
|
group |
BEFREE |
These results indicate that suppression of DDAH2 expression is a culprit for homocysteine-induced impairments of DDAH/ADMA/NOS/NO pathway in endothelial cells, and therapeutic manipulation of DDAH2 expression may be a promising strategy for preventing endothelial dysfunction and cardiovascular diseases associated with hyperhomocysteinemia.
|
23171931 |
2012 |
|
Coronary heart disease
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Association study of dimethylarginine dimethylaminohydrolase 2 gene polymorphisms and coronary heart disease.
|
22923027 |
2012 |